Skip to main content
ENLV
NASDAQ Life Sciences

Allocetra Holds 12-Month Knee OA Benefit; Phase IIb Data Due Mid-2027

Tom Rudovsky · Reported by GlobeNewswire
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
7
Price
$1.9
Mkt Cap
$2.727M
52W Low
$1.73
52W High
$434.4
52W Position info
9.8% above low
Off High info
100% below high
Rel. Volume info
1.9× avg
Market data snapshot near publication time

ENLV is trading near its 52-week low of $1.73 (9.8% above the low) on elevated volume (1.9× avg).

Summary

Enlivex reported 12-month topline data from the Phase IIa stage of its Allocetra knee osteoarthritis trial, showing a durable response in patients 64 and older. At one year, 79.2% of Allocetra patients met the OMERACT-OARSI responder criteria versus 47.6% on placebo (p=0.027), a 66% relative improvement consistent with the 3- and 6-month readouts, when the responder rate was 80% higher for Allocetra than placebo at 3 months (p=0.019) and 39% higher at 6 months (p=0.168). WOMAC pain and function differences versus placebo narrowed by 12 months and lost statistical significance (-12.2 points, p=0.113 for pain; -13.1 points, p=0.067 for function), though the direction still favored treatment, after pain differences of -17.5 points at 3 months (p=0.004) and -15.4 points at 6 months (p=0.012) and function differences of -19.3 points at 3 months (p=0.0008) and -19.5 points at 6 months (p=0.0008); no treatment-related serious adverse events were seen, with adverse events predominantly transient, mild to moderate local knee reactions. The double-blind, randomized, placebo-controlled, multi-centered Phase IIa stage randomized and treated 134 patients, and patient age was the strongest predictor of treatment response, with the treatment effect increasing with age; improvements in patient-reported outcomes were supported by objective physical performance tests and exploratory serum biomarker and imaging analyses, and a single three-injection treatment cycle produced a sustained response through one year. The 12-month data will be presented at ACR Convergence on November 8, 2026, and support the ongoing Phase IIb trial in the same age-related population, with topline results guided for the end of Q2 2027. This is a clinical win for a micro-cap that has been under severe pressure: a 1-for-16 reverse split took effect October 27 and the company disclosed a Nasdaq delisting notice the same day, alongside an October cost-cutting plan that cut about 60% of the workforce. The Phase IIb readout by end-Q2 2027 is the next hard clinical milestone.

Updated with an SEC 6-K filing · What changed

Updates

  1. · SEC 6-K — The 12-month data will be presented at ACR Convergence on November 8, 2026, and Enlivex guides Phase IIb topline data in the same population by end of Q2 2027.

    • Earlier Readouts — At 3 months the responder rate was 80% higher for Allocetra than placebo (p=0.019) and at 6 months 39% higher (p=0.168). WOMAC pain difference vs placebo was -17.5 points at 3 months (p=0.004) and -15.4 points at 6 months (p=0.012); function difference was -19.3 points (p=0.0008) and -19.5 points (p=0.0008).
    • Age Effect — Patient age was the strongest predictor of treatment response, with treatment effect increasing with age.
    • Supporting Measures — Improvements in patient-reported outcomes were supported by objective physical performance tests and exploratory serum biomarker and imaging analyses.
    • Safety — Adverse events were predominantly transient, mild to moderate local knee reactions; no treatment-related serious adverse events observed.
    • Trial Design — The Phase IIa stage was double-blind, randomized, placebo-controlled and multi-centered, with 134 patients randomized and treated.
    • Dosing — A single three-injection treatment cycle of Allocetra produced a sustained treatment response through one year.
    • Presentation Details — Poster title: Durable Clinical Efficacy of an Innovative Intra-Articular Apoptotic Cell Therapy in Knee Osteoarthritis: Age-Related Effect Through One Year. Abstract ID 24454477; Poster Session A (0632–0644): Osteoarthritis – Clinical Poster A.
    All 10 details
    • 3 months: 80% higher responder rate for Allocetra than placebo (p=0.019); 6 months: 39% higher (p=0.168)
    • WOMAC pain difference vs placebo: -17.5 points at 3 months (p=0.004), -15.4 points at 6 months (p=0.012)
    • WOMAC function difference vs placebo: -19.3 points at 3 months (p=0.0008), -19.5 points at 6 months (p=0.0008)
    • Patient age was the strongest predictor of treatment response, with treatment effect increasing with age
    • Improvements in patient-reported outcomes were supported by objective physical performance tests and exploratory serum biomarker and imaging analyses
    • Adverse events were predominantly transient, mild to moderate local knee reactions; no treatment-related serious adverse events observed
    • Phase IIa stage: double-blind, randomized, placebo-controlled, multi-centered; 134 patients randomized and treated
    • Poster title: Durable Clinical Efficacy of an Innovative Intra-Articular Apoptotic Cell Therapy in Knee Osteoarthritis: Age-Related Effect Through One Year
    • Abstract ID 24454477; Poster Session A (0632–0644): Osteoarthritis – Clinical Poster A
    • A single three-injection treatment cycle of Allocetra produced a sustained treatment response through one year

At the time of this announcement, ENLV was trading at $1.90 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.7M. The 52-week trading range was $1.73 to $434.40. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.


Price Chart

Share this article

Copied!

ENLV - Latest Insights

ENLV
Nov 16, 2026, 8:42 AM EST
Source: Seeking Alpha
Importance Score:
7
Price at Filing: $1.08
Real-time Price: $1.06 info
Change: -$0.020 (-2%) info
Market Cap: $1.716M info
ENLV
Nov 16, 2026, 8:00 AM EST
Filing Type: 6-K
Importance Score:
8
Price at Filing: $1.06
Real-time Price: $1.06 info
Change: $0 (0%) info
Market Cap: $1.716M info
ENLV
Oct 27, 2026, 8:59 AM EDT
Source: Seeking Alpha
Importance Score:
8
Price at Filing: $0.1722
Real-time Price: $1.06 info
Change: Reverse Stock Split info
Market Cap: $1.716M info
ENLV
Oct 27, 2026, 8:01 AM EDT
Filing Type: 6-K
Importance Score:
9
Price at Filing: $0.1722
Real-time Price: $1.06 info
Change: Reverse Stock Split info
Market Cap: $1.716M info
ENLV
Oct 22, 2026, 5:17 PM EDT
Filing Type: 6-K
Importance Score:
7
Price at Filing: $2.59
Real-time Price: $1.06 info
Change: Reverse Stock Split info
Market Cap: $1.716M info